Conference
Earn CE
Free Samples
Magazine
Subscribe
Videos
Solutions Lab
Macro/Op-Ed
Practice
Science & Tech
Money
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Dental Market Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Aprea Therapeutics
Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
August 12, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024
June 21, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051
June 17, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial
May 28, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update
May 14, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference
May 13, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 02, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024
April 10, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
March 26, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million
March 11, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers
March 11, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024
March 05, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor
February 06, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics to Present at DDR Inhibitors Summit 2024
January 30, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024
January 04, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
November 09, 2023
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics to Host a Key Opinion Leader (KOL) Event on its Synthetic Lethality (SL) and DNA Damage Response (DDR) Pathways
October 24, 2023
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Unveils Initial Clinical Data on ATRi, ATRN-119, and Pre-Clinical Data on WEE1i, ATRN-1051, at AACR-NCI-EORTC International Conference Supporting Highly Differentiated Synthetic Lethality Portfolio
October 16, 2023
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics Appoints Dr. Jean-Pierre Bizzari to its Board of Directors and Names Dr. Richard Peters as Chairman
August 24, 2023
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics Reports Second Quarter 2023 Financial Results and Provides Update on Business Operations
August 10, 2023
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics to Present at Maxim Virtual Healthcare Conference
June 14, 2023
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics to Present at BIO International Convention
May 30, 2023
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics Reports First Quarter 2023 Financial Results and Provides Update on Business Operations
May 15, 2023
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics Appoints Gabriela Gruia, M.D. to Board of Directors
May 08, 2023
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Update on Business Operations
March 30, 2023
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics Announces Presentation of Preclinical Data on Pipeline Programs at the AACR 2023 Annual Meeting
March 16, 2023
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics to Present at Oppenheimer’s 33rd Annual Healthcare Conference
March 07, 2023
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
March 01, 2023
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics Announces Closing of $5.5 Million Underwritten Public Offering of Common Stock
February 27, 2023
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics Announces Pricing of $5.5 Million Underwritten Public Offering of Common Stock
February 22, 2023
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.